Low-density plating is sufficient to induce cardiac hypertrophy and electrical remodeling in highly purified human iPS cell-derived cardiomyocytes

Journal of Pharmacological and Toxicological Methods

Volumn 69, Issue 2, 2014, Pages 177-188

  Uesugi, Mai ^a,b   Ojima, Atsuko ^a   Taniguchi, Tomohiko ^a   Miyamoto, Norimasa ^a,b   Sawada, Kohei ^a,b  

^a EISAI CO LTD   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cardiac hypertrophy; Cardiomyocytes; Electrical remodeling; Human iPS; KCNQ1; Methods

Indexed keywords

ALPHA ACTININ; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; POTASSIUM CHANNEL KCNQ1; RNA;

ADULT; ANKRD1 GENE; ARTICLE; ATP2A2 GENE; CELL DENSITY; CELL SIZE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE COURSE; DNA MICROARRAY; ELECTRODE; FETUS; FLUORESCENCE MICROSCOPY; GENE; GENE EXPRESSION; HEART BEAT; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; KCNJ2 GENE; KCNQ1 GENE; LOW DENSITY PLATING; MICROARRAY ANALYSIS; MYL2 GENE; NPPA GENE; PLURIPOTENT STEM CELL; POTASSIUM CURRENT; PROCEDURES CONCERNING CELLS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING; CARDIAC MUSCLE CELL; CARDIOMEGALY; CELL CULTURE TECHNIQUE; CELL SEPARATION; CYTOLOGY; ELECTROPHYSIOLOGY; GENE EXPRESSION PROFILING; GENETICS; INDUCED PLURIPOTENT STEM CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE;

IPS;

ADULT; CARDIOMEGALY; CELL CULTURE TECHNIQUES; CELL SEPARATION; ELECTRODES; ELECTROPHYSIOLOGICAL PHENOMENA; GENE EXPRESSION PROFILING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE;

EID: 84895921022     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2013.11.002     Document Type: Article

References (59)

1. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999, 97:175-187.
2. Aihara Y., Kurabayashi M., Saito Y., Ohyama Y., Tanaka T., Takeda S.i, et al. Cardiac ankyrin repeat protein is a novel marker of cardiac hypertrophy: Role of M-CAT element within the promoter. Hypertension 2000, 36:48-53.
3. Ancey C., Menet E., Corbi P., Fredj S., Garcia M., Rucker-Martin C., et al. Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation. Cardiovascular Research 2003, 59:78-85.
4. Anson B.D., Kolaja K.L., Kamp T.J. Opportunities for use of human iPS cells in predictive toxicology. Clinical Pharmacology and Therapeutics 2011, 89:754-758.
5. Bendahhou S., Marionneau C., Haurogne K., Larroque M.M., Derand R., Szuts V., et al. In vitro molecular interactions and distribution of KCNE family with KCNQ1 in the human heart. Cardiovascular Research 2005, 67:529-538.
6. Bernardo B.C., Weeks K.L., Pretorius L., McMullen J.R. Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacology & Therapeutics 2010, 128:191-227.
7. Boheler K.R., Joodi R.N., Qiao H., Juhasz O., Urick A.L., Chuppa S.L., et al. Embryonic stem cell-derived cardiomyocyte heterogeneity and the isolation of immature and committed cells for cardiac remodeling and regeneration. Stem Cells International 2011, 2011:214203.
8. Chen F., Ding S., Lee B.S., Wetzel G.T. Sarcoplasmic reticulum Ca(2+)ATPase and cell contraction in developing rabbit heart. Journal of Molecular and Cellular Cardiology 2000, 32:745-755.
9. Chen H., Huang X.N., Stewart A.F., Sepulveda J.L. Gene expression changes associated with fibronectin-induced cardiac myocyte hypertrophy. Physiological Genomics 2004, 18:273-283.
10. Dedek K., Waldegger S. Colocalization of KCNQ1/KCNE channel subunits in the mouse gastrointestinal tract. Pflügers Archive European Journal of Physiology 2001, 442:896-902.
11. Drazner M.H., Rame J.E., Marino E.K., Gottdiener J.S., Kitzman D.W., Gardin J.M., et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: The Cardiovascular Health Study. Journal of the American College of Cardiology 2004, 43:2207-2215.
12. Egashira T., Yuasa S., Suzuki T., Aizawa Y., Yamakawa H., Matsuhashi T., et al. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovascular Research 2012, 95:419-429.
13. Erokhina I.L., Semenova E.G., Emel'ianova O.I. Human fetal ventricular cardiomyocytes in vitro: Proliferation and differentiation. Tsitologiia 2005, 47:200-206.
14. Flores-Munoz M., Godinho B.M., Almalik A., Nicklin S.A. Adenoviral delivery of angiotensin-(1-7) or angiotensin-(1-9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin type 2 receptor. PloS One 2012, 7:e45564.
15. Foldes G., Mioulane M., Wright J.S., Liu A.Q., Novak P., Merkely B., et al. Modulation of human embryonic stem cell-derived cardiomyocyte growth: A testbed for studying human cardiac hypertrophy?. Journal of Molecular and Cellular Cardiology 2011, 50:367-376.
16. Frey N., Katus H.A., Olson E.N., Hill J.A. Hypertrophy of the heart: A new therapeutic target?. Circulation 2004, 109:1580-1589.
17. Funck-Brentano C., Jaillon P. Rate-corrected QT interval: Techniques and limitations. The American Journal of Cardiology 1993, 72:17B-22B.
18. Ks channels by HMR 1556. Naunyn-Schmiedeberg's Archives of Pharmacology 2000, 362:480-488.
19. Gombosova I., Boknik P., Kirchhefer U., Knapp J., Luss H., Muller F.U., et al. Postnatal changes in contractile time parameters, calcium regulatory proteins, and phosphatases. The American Journal of Physiology 1998, 274:H2123-H2132.
20. Hao J., Kim C.H., Ha T.S., Ahn H.Y. Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. Journal of Veterinary Science 2007, 8:121-129.
21. Harmer S.C., Wilson A.J., Aldridge R., Tinker A. Mechanisms of disease pathogenesis in long QT syndrome type 5. American Journal of Physiology Cell Physiology 2010, 298:C263-C273.
22. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nature Reviews Molecular Cell Biology 2006, 7:589-600.
23. Ivashchenko C.Y., Pipes G.C., Lozinskaya I.M., Lin Z., Xiaoping X., Needle S., et al. Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype. American Journal of Physiology Heart and Circulatory Physiology 2013, 305:H913-H922.
24. Jonckheere A.R. A distribution-free k-sample test against ordered alternatives. Biometrika 1954, 41:133-145.
25. Ks in human ventricular muscle. Circulation 2005, 112:1392-1399.
26. Ju H., Scammel-La Fleur T., Dixon I.M. Altered mRNA abundance of calcium transport genes in cardiac myocytes induced by angiotensin II. Journal of Molecular and Cellular Cardiology 1996, 28:1119-1128.
27. Kattman S.J., Koonce C.H., Swanson B.J., Anson B.D. Stem cells and their derivatives: A renaissance in cardiovascular translational research. Journal of Cardiovascular Translational Research 2011, 4:66-72.
28. Keating M.T., Sanguinetti M.C. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001, 104:569-580.
29. Khan J.M., Lyon A.R., Harding S.E. The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening. British Journal of Pharmacology 2013, 169:304-317.
30. Li G.R., Lau C.P., Leung T.K., Nattel S. Ionic current abnormalities associated with prolonged action potentials in cardiomyocytes from diseased human right ventricles. Heart Rhythm: The Official Journal of the Heart Rhythm Society 2004, 1:460-468.
31. Lundquist A.L., Manderfield L.J., Vanoye C.G., Rogers C.S., Donahue B.S., Chang P.A., et al. Expression of multiple KCNE genes in human heart may enable variable modulation of I(Ks). Journal of Molecular and Cellular Cardiology 2005, 38:277-287.
32. Ma J., Guo L., Fiene S.J., Anson B.D., Thomson J.A., Kamp T.J., et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents. American Journal of Physiology Heart and Circulatory Physiology 2011, 301:H2006-H2017.
33. Maron B.J. Hypertrophic cardiomyopathy: A systematic review. JAMA: The Journal of the American Medical Association 2002, 287:1308-1320.
34. Maron M.S., Olivotto I., Betocchi S., Casey S.A., Lesser J.R., Losi M.A., et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. The New England Journal of Medicine 2003, 348:295-303.
35. Melman Y.F., Krummerman A., McDonald T.V. KCNE regulation of KvLQT1 channels: Structure-function correlates. Trends in Cardiovascular Medicine 2002, 12:182-187.
36. Nakashima H., Gerlach U., Schmidt D., Nattel S. In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: Potential insights into class III actions. Cardiovascular Research 2004, 61:705-714.
37. Ogawa E., Saito Y., Harada M., Kamitani S., Kuwahara K., Miyamoto Y., et al. Outside-in signalling of fibronectin stimulates cardiomyocyte hypertrophy in cultured neonatal rat ventricular myocytes. Journal of Molecular and Cellular Cardiology 2000, 32:765-776.
38. Piquereau J., Novotova M., Fortin D., Garnier A., Ventura-Clapier R., Veksler V., et al. Postnatal development of mouse heart: Formation of energetic microdomains. The Journal of Physiology 2010, 588:2443-2454.
39. Priori S.G., Barhanin J., Hauer R.N., Haverkamp W., Jongsma H.J., Kleber A.G., et al. Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the European Society of Cardiology. European Heart Journal 1999, 20:174-195.
40. Ramakers C., Vos M.A., Doevendans P.A., Schoenmakers M., Wu Y.S., Scicchitano S., et al. Coordinated down-regulation of KCNQ1 and KCNE1 expression contributes to reduction of I(Ks) in canine hypertrophied hearts. Cardiovascular Research 2003, 57:486-496.
41. Roden D.M., Lazzara R., Rosen M., Schwartz P.J., Towbin J., Vincent G.M. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 1996, 94:1996-2012.
42. Sadoshima J., Xu Y., Slayter H.S., Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993, 75:977-984.
43. Sanguinetti M.C., Curran M.E., Zou A., Shen J., Spector P.S., Atkinson D.L., et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 1996, 384:80-83.
44. Schroeder A., Mueller O., Stocker S., Salowsky R., Leiber M., Gassmann M., et al. The RIN: An RNA integrity number for assigning integrity values to RNA measurements. BMC Molecular Biology 2006, 7:3.
45. Shubeita H.E., McDonough P.M., Harris A.N., Knowlton K.U., Glembotski C.C., Brown J.H., et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. The Journal of Biological Chemistry 1990, 265:20555-20562.
46. Ks downregulation and blunted beta-adrenergic activation. Cardiovascular Research 2006, 72:90-100.
47. Taniguchi T., Uesugi M., Arai T., Yoshinaga T., Miyamoto N., Sawada K. Chronic probucol treatment decreases the slow component of the delayed-rectifier potassium current in CHO cells transfected with KCNQ1 and KCNE1: A novel mechanism of QT prolongation. Journal of Cardiovascular Pharmacology 2012, 59:377-386.
48. Terpstra T.J. The asymptotic normality and consistency of Kendall's test against trend, when ties are present in one ranking. Indigationes Mathematicae 1952, 14:327-333.
49. Thomas G.P., Gerlach U., Antzelevitch C. HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. Journal of Cardiovascular Pharmacology 2003, 41:140-147.
50. Tinel N., Diochot S., Borsotto M., Lazdunski M., Barhanin J. KCNE2 confers background current characteristics to the cardiac KCNQ1 potassium channel. The EMBO Journal 2000, 19:6326-6330.
51. Tulloch N.L., Muskheli V., Razumova M.V., Korte F.S., Regnier M., Hauch K.D., et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circulation Research 2011, 109:47-59.
52. Vakili B.A., Okin P.M., Devereux R.B. Prognostic implications of left ventricular hypertrophy. American Heart Journal 2001, 141:334-341.
53. Volders P.G.A., Sipido K.R., Vos M.A., Kulcsar A., Verduyn S.C., Wellens H.J.J. Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes. Circulation 1998, 98:1136-1147.
54. Volders P.G., Sipido K.R., Vos M.A., Spatjens R.L., Leunissen J.D., Carmeliet E., et al. Downregulation of delayed rectifier K(+) currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation 1999, 100:2455-2461.
55. Ks to canine ventricular repolarization: Key role for beta-adrenergic receptor stimulation. Circulation 2003, 107:2753-2760.
56. Wang Q., Curran M.E., Splawski I., Burn T.C., Millholland J.M., VanRaay T.J., et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nature Genetics 1996, 12:17-23.
57. Watkins S.J., Borthwick G.M., Arthur H.M. The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro Cellular & Developmental Biology. Animal 2011, 47:125-131.
58. Yamazaki K., Hihara T., Taniguchi T., Kohmura N., Yoshinaga T., Ito M., et al. A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval. Toxicology in Vitro: An International Journal Published in Association with BIBRA 2012, 26:335-342.
59. Zou M.X., Roy A.A., Zhao Q., Kirshenbaum L.A., Karmazyn M., Chidiac P. RGS2 is upregulated by and attenuates the hypertrophic effect of alpha1-adrenergic activation in cultured ventricular myocytes. Cellular Signalling 2006, 18:1655-1663.